Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference

Rhea-AI Summary

Cognition Therapeutics (Nasdaq: CGTX) announced that its president and CEO, Lisa Ricciardi, will participate in an "unplugged" fireside discussion at the 37th Annual Piper Sandler Healthcare Conference.

The event takes place December 2-4, 2025, with Cognition's presentation scheduled for Wednesday, December 3, 2025 at 4:30 p.m. ET. A live audio webcast will be available and an archived replay will be posted on the company investor relations site for 90 days after the event.

PURCHASE, N.Y., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi will participate in an “unplugged” fireside discussion at the annual Piper Sandler Healthcare Conference. The conference will take place December 2-4, 2025 at The Lotte New York Palace hotel.

Details of Cognition’s fireside discussion are as follows:
Event: 37th Annual Piper Sandler Healthcare Conference  
Date/Time: Wednesday, December 3rd at 4:30p.m. Eastern Time
Webcast: https://event.webcasts.com/starthere.jsp?ei=1742473&tp_key=1130844555

A live audio webcast of the presentation will be available on the company’s investor relations site. An archived replay will be available for 90 days following the event.

About Cognition Therapeutics, Inc.  
Cognition Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system. We recently completed Phase 2 studies of our lead candidate, zervimesine (CT1812) in dementia with Lewy bodies (DLB), mild-to-moderate Alzheimer’s disease and geographic atrophy secondary to dry AMD. The Phase 2 START Study (NCT05531656) in early Alzheimer’s disease is ongoing. We believe zervimesine can regulate pathways that are impaired in these diseases through its interaction with the sigma-2 receptor, a mechanism that is functionally distinct from other approaches for the treatment of degenerative diseases. More about Cognition Therapeutics and our pipeline can be found at https://cogrx.com.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference call, other than statements of historical facts or statements that relate to present facts or current conditions are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of global political changes and global economic conditions, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact Information: Cognition Therapeutics, Inc. info@cogrx.com	Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com

This press release was published by a CLEAR® Verified individual.

FAQ

When will Cognition Therapeutics (CGTX) present at the Piper Sandler Healthcare Conference?

Cognition will present on Wednesday, December 3, 2025 at 4:30 p.m. ET.

How can investors watch the Cognition Therapeutics (CGTX) fireside discussion on December 3, 2025?

Investors can access a live audio webcast via the provided webcast link and on the company's investor relations site.

Will there be a replay of Cognition Therapeutics (CGTX) presentation from the Piper Sandler conference?

Yes. An archived replay will be available on the investor relations site for 90 days after the event.

Who will represent Cognition Therapeutics (CGTX) at the Piper Sandler Healthcare Conference?

The company's president and CEO, Lisa Ricciardi, will participate in the fireside discussion.

What are the dates and location of the 37th Annual Piper Sandler Healthcare Conference where CGTX will appear?

The conference runs December 2-4, 2025 at The Lotte New York Palace hotel in New York.